Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Angiotensin II Type 2 Receptor (AT2) is a G protein-coupled receptor that is part of the renin-angiotensin system (RAS). It generally counteracts the effects of the AT1 receptor, promoting vasodilation, sodium excretion, and inhibiting cell growth. It is highly expressed during fetal development but has lower expression in adults, although expression can increase under pathological conditions. Selective activation of the AT2 receptor may have therapeutic potential for cardiovascular and kidney protection, as well as anti-inflammatory and metabolic benefits.
Agonists of the AT2 receptor promote vasodilation, natriuresis, anti-proliferation, and apoptosis, counteracting the effects of AT1 receptor activation. They may also mediate anti-inflammatory effects and improve insulin sensitivity.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Angiotensin II Receptor Type 2 (AT2).